How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?  

All of us caring for patients with a lung cancer diagnosis face a very challenging “now what” scenario following publications of many studies demonstrating benefits of a neoadjuvant and/or perioperative approach for the treatment of patients with resectable NSCLC with already 2 FDA appro...

Current NCCN guidelines have listed two options in this setting: Nivolumab and platinum doublet chemotherapy every 3 weeks for 3 cycles followed by surgery or Pembrolizumab and platinum doublet chemotherapy every 3 weeks for 4 cycles followed by continued single agent pembrolizumab as adjuvant treat...